KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Current Deferred Tax Assets: 2012-2015

Historic Current Deferred Tax Assets for Regeneron Pharmaceuticals (REGN) over the last 3 years, with Sep 2015 value amounting to $60.5 million.

  • Regeneron Pharmaceuticals' Current Deferred Tax Assets rose 23.50% to $60.5 million in Q3 2015 from the same period last year, while for Sep 2015 it was $60.5 million, marking a year-over-year increase of 23.50%. This contributed to the annual value of $46.2 million for FY2014, which is 3.36% up from last year.
  • Regeneron Pharmaceuticals' Current Deferred Tax Assets amounted to $60.5 million in Q3 2015, which was down 13.05% from $69.6 million recorded in Q2 2015.
  • Over the past 5 years, Regeneron Pharmaceuticals' Current Deferred Tax Assets peaked at $148.1 million during Q4 2012, and registered a low of $36.6 million during Q1 2014.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Current Deferred Tax Assets value was $46.2 million (recorded in 2014), while the average stood at $53.1 million.
  • In the last 5 years, Regeneron Pharmaceuticals' Current Deferred Tax Assets plummeted by 69.84% in 2013 and then soared by 86.65% in 2015.
  • Quarterly analysis of 4 years shows Regeneron Pharmaceuticals' Current Deferred Tax Assets stood at $148.1 million in 2012, then crashed by 69.84% to $44.7 million in 2013, then grew by 3.36% to $46.2 million in 2014, then climbed by 23.50% to $60.5 million in 2015.
  • Its last three reported values are $60.5 million in Q3 2015, $69.6 million for Q2 2015, and $62.1 million during Q1 2015.